DR. CHRISTOPHER DAVID GOCKE, M.D.
Medical Practice in Baltimore, MD
License number
Maryland D0056461
Category
Medical Practice
Type
Molecular Genetic Pathology
License number
Maryland D0056461
Category
Medical Practice
Type
Anatomic Pathology & Clinical Pathology
Address
Address
2
600 N Wolfe St Park, Baltimore, MD 21287
10310 Cromwell Ct, Ellicott, MD 21042
10310 Cromwell Ct, Ellicott, MD 21042
Phone
(410) 955-8363
(410) 203-1310
(410) 203-1310
Personal information
See more information about CHRISTOPHER DAVID GOCKE at radaris.comName
Address
Phone
10310 Cromwell Ct, Ellicott City, MD 21042
10310 Cromwell Ct, Ellicott City, MD 21042
Professional information
Dr. Christopher D Gocke, Baltimore MD - MD (Doctor of Medicine)
Specialties:
Molecular Genetic Pathology
Address:
600 N Wolfe St, Baltimore 21287
(410) 955-8363 (Phone)
JOHNS HOPKINS HOSPITAL
601 N Caroline St, Baltimore 21287
(410) 955-3071 (Phone), (410) 955-6526 (Fax)
(410) 955-8363 (Phone)
JOHNS HOPKINS HOSPITAL
601 N Caroline St, Baltimore 21287
(410) 955-3071 (Phone), (410) 955-6526 (Fax)
Certifications:
Anatomic Pathology, 1991, Molecular Genetic Pathology, 2005
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
600 N Wolfe St, Baltimore 21287
JOHNS HOPKINS HOSPITAL
601 N Caroline St, Baltimore 21287
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287
JOHNS HOPKINS HOSPITAL
601 N Caroline St, Baltimore 21287
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287
Education:
Medical School
Umdnj-Robt W Johnson Med Sch
Graduated: 1985
Umdnj-Robt W Johnson Med Sch
Graduated: 1985
Christopher David Gocke, Baltimore MD
Specialties:
Pathology, Anatomic Pathology, Molecular Genetic Pathology, Anatomic Pathology & Clinical Pathology, Molecular Genetic Pathology
Work:
The Johns Hopkins Hospital
600 N Wolfe St, Baltimore, MD 21287 Johns Hopkins Bayview Medical Center
4940 Eastern Ave, Baltimore, MD 21224 Johns Hopkins Outpatient Center
601 N Caroline St, Baltimore, MD 21287
600 N Wolfe St, Baltimore, MD 21287 Johns Hopkins Bayview Medical Center
4940 Eastern Ave, Baltimore, MD 21224 Johns Hopkins Outpatient Center
601 N Caroline St, Baltimore, MD 21287
Education:
UMDNJ Robert Wood Johnson (1985)
Christopher David Gocke, Baltimore MD
Specialties:
Pathologist
Address:
600 N Wolfe St, Baltimore, MD 21287
600 N Wolfe, Baltimore, MD 21287
600 N Wolfe, Baltimore, MD 21287
Education:
Doctor of Medicine*
Board certifications:
American Board of Pathology Certification in Anatomic Pathology (Pathology)*, American Board of Pathology Sub-certificate in Molecular Genetic Pathology (Pathology)*
Detection Of Extracellular Tumor-Associated Nucleic Acid In Blood Plasma Or Serum Using Nucleic Acid Amplification Assays
US Patent:
7282335, Oct 16, 2007
Filed:
Aug 31, 2005
Appl. No.:
11/217120
Inventors:
Christopher Gocke - Ellicott City MD, US
Michael Kopreski - Long Valley NJ, US
Michael Kopreski - Long Valley NJ, US
Assignee:
The Pennsylvania State University - University Park PA
International Classification:
C12Q 1/68, C12P 19/34
US Classification:
435 6, 435 912
Abstract:
This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such as oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic or proliferative disease.
Detection Of Extracellular Translocated Tumor-Associated Nucleic Acid In Blood Plasma Or Serum Using Nucleic Acid Amplification Assays
US Patent:
7288380, Oct 30, 2007
Filed:
Aug 15, 2005
Appl. No.:
11/204191
Inventors:
Christopher Gocke - Ellicott City MD, US
Michael Kopreski - Long Valley NJ, US
Michael Kopreski - Long Valley NJ, US
Assignee:
The Pennsylvania State University - University Park PA
International Classification:
C12Q 1/68, C12P 19/34
US Classification:
435 6, 435 912
Abstract:
This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such as oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic or proliferative disease.
Detection Of Extracellular Tumor-Associated Nucleic Acid In Blood Plasma Or Serum Using Nucleic Acid Amplification Assays
US Patent:
7208275, Apr 24, 2007
Filed:
Aug 22, 2003
Appl. No.:
10/646397
Inventors:
Christopher D. Gocke - Ellicott City MD, US
Michael S. Kopreski - Long Valley NJ, US
Michael S. Kopreski - Long Valley NJ, US
Assignee:
The Penn State Research Foundation - University Park PA
International Classification:
C12Q 1/68, C12P 19/34
US Classification:
435 6, 435 912
Abstract:
This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such as oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic or proliferative disease.
Detection Of Extracellular Tumor-Associated Nucleic Acid In Blood Plasma Or Serum Using Nucleic Acid Amplification Assays
US Patent:
7399592, Jul 15, 2008
Filed:
Jun 1, 2006
Appl. No.:
11/421492
Inventors:
Christopher D. Gocke - Ellicott City MD, US
Michael S. Kopreski - Long Valley NJ, US
Floyd A. Benko - Palmyra PA, US
Michael S. Kopreski - Long Valley NJ, US
Floyd A. Benko - Palmyra PA, US
Assignee:
The Penn State Research Foundation - University Park PA
International Classification:
C12Q 1/68, C12P 19/34
US Classification:
435 6, 435 912
Abstract:
This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or maligant neoplasms in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such as oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic or proliferative disease.
Detection Of Extracellular Tumor-Associated Nucleic Acid In Blood Plasma Or Serum Using Nucleic Acid Amplification Assay
US Patent:
7935484, May 3, 2011
Filed:
Apr 2, 2007
Appl. No.:
11/695421
Inventors:
Christopher D. Gocke - Ellicott City MD, US
Michael S. Kopreski - Long Valley NJ, US
Michael S. Kopreski - Long Valley NJ, US
Assignee:
The Penn State Research Foundation - University Park PA
International Classification:
C12Q 1/68, C07H 21/04, C12P 19/34
US Classification:
435 6, 435 912, 536 2433
Abstract:
This invention relates to detection of specific extracellular nucleic acid in human or animal blood plasma or serum associated with disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA including non-mutated hypermethylated DNA, and to methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA including non-mutated hypermethylated DNA found in blood plasma or serum. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of neoplasia in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the non-mutated hypermethylated nucleic acid of the neoplasm in plasma or serum fractions.
Method Of Detecting Tumor-Associated Dna In Plasma Or Serum From Humans Without Cancer
US Patent:
7935487, May 3, 2011
Filed:
Aug 10, 2010
Appl. No.:
12/854039
Inventors:
Christopher D. Gocke - Ellicott City MD, US
Michael S. Kopreski - Long Valley NJ, US
Michael S. Kopreski - Long Valley NJ, US
Assignee:
The Penn State Research Foundation - University Park PA
International Classification:
C12Q 1/68, C12P 19/34
US Classification:
435 6, 435 912
Abstract:
This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in human or other animals The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention thereby provides methods for early identification of colorectal, pancreatic, lung, breast, bladder, ovarian, lymphoma and all other malignancies carrying tumor-related mutations of DNA and methods for monitoring cancer and other neoplastic disorders in humans and other animals.
Detection Of Extracellular Tumor-Associated Nucleic Acid In Blood Plasma Or Serum
US Patent:
8048629, Nov 1, 2011
Filed:
Aug 7, 2007
Appl. No.:
11/835398
Inventors:
Christopher D. Gocke - Ellicott City MD, US
Michael S. Kopreski - Long Valley NJ, US
Michael S. Kopreski - Long Valley NJ, US
Assignee:
The Penn State Research Foundation - University Park PA
International Classification:
C12Q 1/68, C12P 19/34, A61K 48/00
US Classification:
435 612, 435 912, 514 44
Abstract:
This invention relates to detection of specific extracellular DNA in plasma or serum fractions of human or animal blood associated with neoplastic, pre-malignant or proliferative disease. Specifically, the invention relates to detection tumor-associated DNA, and to those methods of detecting and monitoring tumor-associated DNA found in the plasma or serum fraction of blood by using DNA extraction and amplification with or without enrichment for DNA. The invention allows the selection and monitoring of patients for various cancer therapies including receptor tyrosine kinase inhibitor therapies.